Purchase this article with an account.
Libei Zhao, xuetao Huang, Wenxiang Lin, Ding Lin; Sustained controllable sub-Tenon infusion for delivery of Dexamethasone to the experimental autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5713. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the intraocular distribution and diffusion of Dexamethasone（DEX） in experimental autoimmune uveitis(EAU) using a novel sustained controllable sub-Tenon infusion(SCSI) approach
The rabbit model of uveitis was induced by first injection the emulsion of Bovine serum albumin (BSA) and Complete Freund's adjuvant (CFA), and one week later intravitreal injection of BSA, eighty adult New Zealand White rabbits were randomly assigned to two groups: EAU and normal rabbits groups, they were received DEX by sustained controllable sub-Tenon delivery with the flow rate of 0.1 ml/h for 24 h in the right eyes. Rabbits were killed in both groups of eight at 1, 3, 6, 10, 12, 16, 20 and 24 h. The DEX concentration of the ocular tissues of the right eye was analyzed by Shimadzu LC–MS 2010 system.
In EAU group, during observed 24h, the mean DEX level in collected samples from highest to lowest following in order: sclera, cornea, retina/choroid, iris, plasma, aqueous humor, and vitreous body. In addition, the DEX concentration of posterior segment in EAU group was significantly higher than that in normal group at each time. Levels of DEX were higher at 1, 3, 6h in EAU than normal group in plasma(p＜0.05), In two groups the highest level of DEX were appeared at 1h in sclera, aqueous fluid, vitreous and at 3h in cornea, plasma, the DEX concentration of iris and retina/choroid reached maximum at 1h in EAU group and at 3h in normal group.
This study demonstrates the ability to maintain moderate concentration of DEX in EAU by the SCSI. The proposed device holds great promise in managing uveitis and other ocular inflammation cases.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only